Objective To evaluate the clinical efficacy and safety of weekly paclitaxel plus carboplatin and trastuzumab as neoadjuvant therapy for HER2 positive breast cancers. Methods Forty-two patients with HER-2 positive breast cancer were assigned to receive four cycles of paclitaxel plus carboplatin and trastuzum-ab as neoadjuvant therapy with dose of paclitaxel 80 mg/m2 and carboplatin AUC=1.5, given day1, out of every 3weeks for a total of 12 weeks; and received weekly trastuzumab. Then the overall clinical efficacy and adverse reactions were observed. The primary end point was pCR. Results Forty-one patients completed four cycles of paclitaxel plus carboplatin and trastuzumab as neoadjuvant therapy.The overall response (OR) rate was 97.6%, clinical complete response (CR) was achieved in 25 cases, partial response (PR) in 16 cases. The pCR was seen in 23 cases (54.8%). Adverse reactions were mainly for bone marrow suppression and hair loss. None of them suffered from severe cardiotoxicity. Conclusion This four cycles therapy of weekly paclitaxel plus carboplatin and trastuzumab was highly effective and tolerable as neoadjuvant therapy for HER2 positive breast cancer.%目的:观察紫杉醇联合卡铂行新辅助化疗加曲妥珠单抗方案在HER2阳性乳腺癌中的疗效及安全性.方法:42例HER2阳性的乳腺癌患者,均行4个疗程紫杉醇联合卡铂单周化疗方案加曲妥珠单抗的治疗;紫杉醇80 mg/m2,卡铂AUC=1.5,d1静脉点滴,每周重复;每3周为1疗程,共12周;同时加曲妥珠单抗(赫赛汀)单周治疗;评价其疗效及不良反应,主要观察指标为pCR.结果:41例完成了4疗程的紫杉醇联合卡铂新辅助化疗加曲妥珠单抗治疗,临床总有效率97.6%,临床完全缓解25例( 59.5%),肿瘤部分缓解16例(38.1%),病理完全缓解23例(54.8%);不良反应主要为骨髓抑制和脱发,无心脏毒副作用.结论:在HER-2阳性乳腺癌的新辅助化疗中,4疗程的紫杉醇联合卡铂单周化疗方案加曲妥珠单抗的治疗具有较好的疗效及耐受性.
展开▼
